Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

doi:10.1053/j.gastro.2020.05.053

. 2020 Sep;159(3):1129-1131.e3.

doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Daniel E Freedberg¹, Joseph Conigliaro², Timothy C Wang³, Kevin J Tracey⁴, Michael V Callahan⁵, Julian A Abrams⁶; Famotidine Research Group

Collaborators, Affiliations

Collaborators

Famotidine Research Group:
Magdalena E Sobieszczyk, David D Markowitz, Aakriti Gupta, Max R O'Donnell, Jianhua Li, David A Tuveson, Zhezhen Jin, William C Turner, Donald W Landry

Affiliations

¹ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York. Electronic address: def2004@cumc.columbia.edu.
² Division of General Internal Medicine, Department of Medicine, Northwell Health, Manhasset, New York; Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
³ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York.
⁴ Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York.
⁵ Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts; Office of the Assistant Secretary for Public Health Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC.
⁶ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York. Electronic address: ja660@cumc.columbia.edu.

PMID: 32446698
PMCID: PMC7242191
DOI: 10.1053/j.gastro.2020.05.053

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Daniel E Freedberg et al. Gastroenterology. 2020 Sep.

. 2020 Sep;159(3):1129-1131.e3.

doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.

Authors

Daniel E Freedberg¹, Joseph Conigliaro², Timothy C Wang³, Kevin J Tracey⁴, Michael V Callahan⁵, Julian A Abrams⁶; Famotidine Research Group

Collaborators

Famotidine Research Group:
Magdalena E Sobieszczyk, David D Markowitz, Aakriti Gupta, Max R O'Donnell, Jianhua Li, David A Tuveson, Zhezhen Jin, William C Turner, Donald W Landry

Affiliations

¹ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York. Electronic address: def2004@cumc.columbia.edu.
² Division of General Internal Medicine, Department of Medicine, Northwell Health, Manhasset, New York; Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
³ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York.
⁴ Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York.
⁵ Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts; Office of the Assistant Secretary for Public Health Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC.
⁶ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York. Electronic address: ja660@cumc.columbia.edu.

PMID: 32446698
PMCID: PMC7242191
DOI: 10.1053/j.gastro.2020.05.053

No abstract available

Keywords: Coronavirus 2019; Famotidine; Histamine-2 Receptor Antagonists; SARS-CoV-2.

PubMed Disclaimer

Figures

**Figure 1**
Kaplan-Meier plot showing (A) intubation-free survival and (B) survival through a maximum of 30 days after hospital admission, stratified by use of famotidine. Patients were included in the study if they survived without intubation for 2 days following hospital admission. Use of famotidine was classified as present if it was received within the first 24 hours following hospital admission (any dose, form of administration, or duration) and otherwise as absent. The at-risk time began on hospital day 2 (indicated with a *dashed red line*) and patients were followed until hospital day 30. This study design avoided potential for immortal time bias because the exposure was classified before the start of the at-risk period.

See this image and copyright information in PMC

Comment in

Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study.
Cheung KS, Hung IFN, Leung WK. Cheung KS, et al. Gastroenterology. 2021 Apr;160(5):1898-1899. doi: 10.1053/j.gastro.2020.05.098. Epub 2020 Jul 16. Gastroenterology. 2021. PMID: 32682763 Free PMC article. No abstract available.
What Underlies the Benefit of Famotidine Formulations Used During COVID-19?
Singh VP, El-Kurdi B, Rood C. Singh VP, et al. Gastroenterology. 2021 Apr;160(5):1899-1900. doi: 10.1053/j.gastro.2020.07.051. Epub 2020 Aug 7. Gastroenterology. 2021. PMID: 32777281 Free PMC article. No abstract available.
Reply.
Freedberg DE, Wang TC, Abrams JA. Freedberg DE, et al. Gastroenterology. 2021 Apr;160(5):1900-1901. doi: 10.1053/j.gastro.2021.01.013. Epub 2021 Jan 13. Gastroenterology. 2021. PMID: 33453230 Free PMC article. No abstract available.

Cited by

Famotidine increases cellular phospho-tyrosine levels.
Zubiete-Franco I, Tonks NK. Zubiete-Franco I, et al. Biochem Biophys Res Commun. 2024 Nov 19;734:150763. doi: 10.1016/j.bbrc.2024.150763. Epub 2024 Sep 28. Biochem Biophys Res Commun. 2024. PMID: 39362028
GERD: Latest update on acid-suppressant drugs.
Al-Frejat Z, Martini N, Esper A, Al-Frejat D, Younes S, Hanna M. Al-Frejat Z, et al. Curr Res Pharmacol Drug Discov. 2024 Aug 23;7:100198. doi: 10.1016/j.crphar.2024.100198. eCollection 2024. Curr Res Pharmacol Drug Discov. 2024. PMID: 39282236 Free PMC article.
Unraveling the relevance of SARS-Cov-2 infection and ferroptosis within the heart of COVID-19 patients.
Alizadeh Saghati A, Sharifi Z, Hatamikhah M, Salimi M, Talkhabi M. Alizadeh Saghati A, et al. Heliyon. 2024 Aug 24;10(17):e36567. doi: 10.1016/j.heliyon.2024.e36567. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39263089 Free PMC article.
One-year post-acute COVID-19 syndrome and mortality in South Korea: a nationwide matched cohort study using claims data.
Won JH, Hong Y, Kim S, Lee H. Won JH, et al. Front Public Health. 2024 Jul 10;12:1403153. doi: 10.3389/fpubh.2024.1403153. eCollection 2024. Front Public Health. 2024. PMID: 39050601 Free PMC article.
Retrospective evaluation of the effect of acid suppressant drugs on leukocyte ratios in dogs with mast cell tumors.
Oberholtzer S, Zhu X, Dedeaux A, Martin O, Gould EN. Oberholtzer S, et al. J Vet Intern Med. 2024 Jul-Aug;38(4):2305-2315. doi: 10.1111/jvim.17133. Epub 2024 Jun 18. J Vet Intern Med. 2024. PMID: 38888250 Free PMC article.

See all "Cited by" articles

References

1. Gottschlich M.M., DeLegge M.H., Guenter P. American Society for Parenteral and Enteral Nutrition; Silver Spring, MD: 2007. American Society for Parenteral and Enteral Nutrition.
1. Bourinbaiar A.S., Fruhstorfer E.C. Life Sci. 1996;59:PL365–370. - PubMed
1. Wu C., Liu Y., Yang Y. Acta Pharm Sin B. 2020;10:766–788. - PMC - PubMed
1. Anand K., Ziebuhr J., Wadhwani P. Science. 2003;300:1763–1767. - PubMed
1. Chen X., Deng H., Churchill M.J. Cell Stem Cell. 2017;21:747–760.e7. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal

[1] Gottschlich M.M., DeLegge M.H., Guenter P. American Society for Parenteral and Enteral Nutrition; Silver Spring, MD: 2007. American Society for Parenteral and Enteral Nutrition.

[2] Gottschlich M.M., DeLegge M.H., Guenter P. American Society for Parenteral and Enteral Nutrition; Silver Spring, MD: 2007. American Society for Parenteral and Enteral Nutrition.

[3] Bourinbaiar A.S., Fruhstorfer E.C. Life Sci. 1996;59:PL365–370. - PubMed

[4] Bourinbaiar A.S., Fruhstorfer E.C. Life Sci. 1996;59:PL365–370. - PubMed

[5] Wu C., Liu Y., Yang Y. Acta Pharm Sin B. 2020;10:766–788. - PMC - PubMed

[6] Wu C., Liu Y., Yang Y. Acta Pharm Sin B. 2020;10:766–788. - PMC - PubMed

[7] Anand K., Ziebuhr J., Wadhwani P. Science. 2003;300:1763–1767. - PubMed

[8] Anand K., Ziebuhr J., Wadhwani P. Science. 2003;300:1763–1767. - PubMed

[9] Chen X., Deng H., Churchill M.J. Cell Stem Cell. 2017;21:747–760.e7. - PMC - PubMed

[10] Chen X., Deng H., Churchill M.J. Cell Stem Cell. 2017;21:747–760.e7. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Collaborators

Affiliations

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Authors

Collaborators

Affiliations

Figures

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous

Figures

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous